

CERTIFICATE OF ANALYSIS

Public sample verification record. Live customer batches require QA confirmation before file release.

PRODUCT NAME	BATCH NO.
Retatrutide 20mg + Trizepatide 40mg	PS-R2T4-2606-013
MOLECULAR FORMULA	SPECIFICATION
Available on request	60 mg / vial
MOLECULAR WEIGHT	MFG. DATE
Available on request	20 June 2026
CAS NO.	RETEST DATE
Batch-specific identity	20 June 2028
COA NO.	STORAGE
COA-PS-R2T4-2606-013	-20 °C, protect from light

TEST ITEM	ACCEPTANCE CRITERIA	RESULT	STATUS
Appearance	White to off-white lyophilized powder	White to off-white lyophilized powder	Pass
Identification (LC-MS)	Consistent with reference standard or controlled identity file	Conforms	Pass
Peptide Purity (RP-HPLC)	NLT 98.0%	98.91%	Pass
Related Impurities (HPLC)	Each impurity NMT 1.0%; total NMT 2.0%	Each <= 0.51%; total 1.13%	Pass
Mass Spectrum (ESI-MS)	Reference mass profile or component identity per controlled batch file	Conforms to batch identity file	Pass
Peptide Content (Assay)	NLT 90.0% on dry basis	97.9%	Pass
Water Content (Karl Fischer)	NMT 7.0%	2.5%	Pass
Residual Solvents (GC)	ACN NMT 410 ppm; DCM NMT 600 ppm; MTBE NMT 5000 ppm	ACN 224 ppm; others N.D.	Pass
Heavy Metals (as Pb)	NMT 10 ppm	< 2 ppm	Pass
Bacterial Endotoxins	NMT 1 EU/mg	< 0.05 EU/mg	Pass
Microbial Limits	TAMC NMT 100 cfu/g; TYMC NMT 100 cfu/g	TAMC < 20; TYMC < 20 cfu/g	Pass
Fill Content	Catalog fill +/-10%	60 mg / vial	Pass

QA APPROVAL

Testing completed 20 June 2026

Kevin Fang

Quality Assurance Reviewer - Kevin Fang - 21 June 2026

DOCUMENT CONTROL

RELEASE DECISION

Approved for sample verification

DOCUMENT STATUS

Demo record - QA confirmation required

Sample notice: This public record demonstrates the PeptideSource verification format. Current customer lots require QA confirmation, order context, or controlled access before full release files are displayed.